Medios AG fulfils forecast for financial year 2018 and is expecting to set new records in 2019

Corporate News

Medios AG fulfils forecast for financial year 2018 and is expecting to set new records in 2019

• Sales increase by 29.3 per cent to EUR 327.9 million in the financial year 2018
• Adjusted EBITDA* rise by 41.6 per cent to EUR 12.1 million
• Adjusted EBT* climb by 37.7 per cent to EUR 11.0 million
• Management Board is expecting further record figures for 2019, with sales of EUR 400 to 410 million and further improvement in earnings margins

Berlin, 14 February 2019 - Medios AG ('Medios'), one of the leading Specialty Pharma companies in Germany, is expecting another record year after significant sales and earnings growth in 2018. According to preliminary calculations (IFRS), group sales in the period from January to December 2018 increased year on year by 29.3 per cent to EUR 327.9 million (previous year EUR 253.6 million). Group earnings before interest, taxes, depreciation and amortization (EBITDA), adjusted for extraordinary expenses*, rose by 41.6 per cent to EUR 12.1 million (previous year EUR 8.5 million). Group earnings before taxes (EBT), adjusted for extraordinary expenses*, climbed by 37.7 per cent to EUR 11.0 million (previous year EUR 8.0 million). Thereby, all the forecasts of the Management Board for the financial year 2018 were met.

Manfred Schneider, CEO of Medios AG: '2018 was another record year for Medios, thanks to the consistent implementation of our growth strategy and to the ongoing high demand for individualised therapies. We have expanded our partner network, increased our product range and extended our indication areas. In the financial year 2019, we want to continue on our dynamic growth path. Therefore, we are especially investing strongly in setting up a new business unit, 'Drug Safety', and in establishing our new 'Medios Apotheke' brand.'

Matthias Gärtner, CFO of Medios AG: 'We have achieved our ambitious targets in the financial year 2018. Our operating earnings rose faster than sales again. Thereby, we have become even more profitable. We intend to maintain this trend in 2019, while continuing our high growth rate.'

Due to the acquisitions in the financial year 2018 and the further company growth, Medios expects higher depreciation and amortisation from the current year onwards. In order to illustrate this adequately in the financial reports and to present its operating performance transparently, Medios is including EBITDA as another key performance indicator in its financial reporting with immediate effect.

Further record figures expected for 2019
For the financial year 2019, the Management Board is expecting group sales of EUR 400 to 410 million, adjusted EBITDA* of EUR 16 to 17 million and adjusted EBT* of EUR 14 to 15 million. This represents sales growth of 22.0 to 25.0 per cent as well as a further increase in adjusted operating earnings* with improved earnings margins. As far as currently foreseeable, the forecasts include both the effects of the planned 'Act for more Drug Safety' on the course of Medios' business as well as additional investments in the Drug Safety business unit and the establishment of the 'Medios Apotheke' brand.

-------------------

* Adjusted for extraordinary expenses of around EUR 3.47 million in total for a) stock options totalling EUR 2.51 million from the financial years 2017 and 2018 (non-cash), b) start-up expenses in the financial year 2018 of EUR 0.64 million for the laboratories acquired in September 2017 and c) of EUR 0.32 million for the acquisition of the operating units from BerlinApotheke Schneider & Oleski oHG in the financial year 2018 (non-cash)

About Medios AG
Medios AG is one of the leading Specialty Pharma companies in Germany. As a specialist for the provision of Specialty Pharma drugs to patients and GMP-certified provider of individualized therapies, Medios covers substantial elements of the supply chain in this field and follows the highest international quality standards. Usually, Specialty Pharma drugs are high-priced medicines for rare and/or chronic diseases. Individualized therapies are, for example, infusions that are compiled and produced on the basis of individual diseases and parameters like body weight and surface. It is Medios' aim to provide integrated solutions along the value chain to partners and clients, thereby ensuring an optimal pharmaceutical care for patients.

Medios AG is Germany's first publicly listed Specialty Pharma company. The share (WKN: A1MMCC, ISIN: DE000A1MMCC8) is listed in the Regulated Market of the Frankfurt Stock Exchange (General Standard) and Hamburg-Hannover Stock Exchange.

Contact
Kirchhoff Consult AG
Nikolaus Hammerschmidt
Borselstraße 20
22765 Hamburg
Germany
Tel.: +49 40 60918618
Fax: +49 40 60918660
E-mail: nikolaus.hammerschmidt@kirchhoff.de
www.kirchhoff.de

Disclaimer
This notification contains forward-looking statements that are subject to certain risks and uncertainties. Future results may significantly deviate from currently expected results, specifically due to various risk factors and uncertainties such as changes in business, economic, and competitive circumstances, exchange rate fluctuations, uncertainties about legal disputes or investigations, and the availability of financial resources. Medios AG assumes no responsibility whatsoever for updating the forward-looking statements contained in this notification.